Benvenue Medical completed a US $60MM financing round. Proceeds will support U.S. commercialization of the Luna® 3D Interbody Fusion System for treating degenerative disc disease and the Kiva® Vertebral Compression Fracture Treatment System.
The financing represents $23MM in equity supplemented with $37MM in debt.
Cleared by FDA in 4Q14 and launched in 4Q15, Luna 3D features a small profile PEEK implant that expands in three dimensions within the disc space. Spine Wave and Expanding Orthopedics also have expanding interbody technologies in their portfolios.
Cleared by FDA and launched in 1Q14, the Kiva system uses expandable implant technology to create a predictable structural support for the vertebral body and a reservoir to direct and contain bone cement.
To introduce Kiva, Benvenue armed itself with three comparative studies with a total of more than 500 patients to demonstrate its effectiveness. Robert Weigle of Benvenue discussed the company’s clinical data plan with BONEZONE® in 2014.
Benvenue Medical completed a US $60MM financing round. Proceeds will support U.S. commercialization of the Luna® 3D Interbody Fusion System for treating degenerative disc disease and the Kiva® Vertebral Compression Fracture Treatment System.
The financing represents $23MM in equity supplemented with $37MM in debt.
Cleared by FDA in...
Benvenue Medical completed a US $60MM financing round. Proceeds will support U.S. commercialization of the Luna® 3D Interbody Fusion System for treating degenerative disc disease and the Kiva® Vertebral Compression Fracture Treatment System.
The financing represents $23MM in equity supplemented with $37MM in debt.
Cleared by FDA in 4Q14 and launched in 4Q15, Luna 3D features a small profile PEEK implant that expands in three dimensions within the disc space. Spine Wave and Expanding Orthopedics also have expanding interbody technologies in their portfolios.
Cleared by FDA and launched in 1Q14, the Kiva system uses expandable implant technology to create a predictable structural support for the vertebral body and a reservoir to direct and contain bone cement.
To introduce Kiva, Benvenue armed itself with three comparative studies with a total of more than 500 patients to demonstrate its effectiveness. Robert Weigle of Benvenue discussed the company’s clinical data plan with BONEZONE® in 2014.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
